Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRANCH-HF: PF-07328948 in Adults With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
jRCT2031250168Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Aug 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of PF-07328948 in heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) (4 arms), sponsored by Pfizer. Primary endpoints: Number of participants with clinical events, Change from baseline in 6-minute walk test distance (6MWD) and 1 more. Started Aug 2025; status: recruiting.
02
Drugs
PF-07328948
03
Conditions
heart failure with mid-range ejection fraction (HFmrEF)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on jRCT2031250168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250168.